About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

PARP Inhibitor Effective For Certain Triple-negative Breast Cancers

by Hannah Joy on November 1, 2017 at 5:02 PM
Font : A-A+

PARP Inhibitor Effective For Certain Triple-negative Breast Cancers

Pharmacological inhibitor (PARP) talazoparib could be effective for certain triple-negative breast cancers (TNBC) that lack BRCA mutation, especially those that had other alterations in DNA damage-repair pathways, reveals a new study.

The study was published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Advertisement


The authors are Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and Nellie B. Connally Chair in Breast Cancer Research at The University of Texas MD Anderson Cancer Center in Houston.

"Patients with triple-negative breast cancer who do not respond to neoadjuvant [preoperative] chemotherapy have a decreased chance of long-term survival, and there is a great need for new treatment options," said Meric-Bernstam.
Advertisement

"Developing animal models that are well characterized gives us an opportunity to test new agents and better understand how to best treat these patients."

Because PDXs are tumor models derived directly from patient tumors and grown in mice, they may better reflect the complexity of human tumors than traditional models, she explained.

"Ultimately, we would like to better deliver personalized cancer therapy by understanding how we can best match therapies to patients," she said.

The researchers developed 26 PDXs using tumors from 25 patients, of which 24 were TNBC; 22 PDXs were derived from residual tumors after neoadjuvant chemotherapy. Their research showed that the PDX models varied significantly in their responsiveness to different standard-of-care chemotherapies as well as targeted therapies in development.

"The PDX models we generated varied dramatically in their genomic characteristics, potentially giving insight into why it has been challenging to truly personalize cancer therapy," Meric-Bernstam noted.

Based on data obtained by sequencing the tumor exomes, the researchers tested several investigational agents: the pan-PI3K inhibitor buparlisib against seven PDXs, the mTOR inhibitor TAK228 against eight PDXs, the MEK1/2 inhibitor trametinib against eight PDXs, and the PARP1/2 inhibitor talazoparib against 13 PDXs. They found that buparlisib, trametinib, and TAK228 had growth inhibitory effects, but they did not cause regression of any of the PDXs against which they were tested.

"Among targeted therapies, the efficacy of PARP inhibitors was most striking," noted Meric-Bernstam. Of the PDXs treated with talazoparib, five regressed and one showed stable disease for at least 28 days. Four of these five PDXs did not harbor germline BRCA1/2 mutations, but had alterations in other DNA repair pathways, including ATM deletion and other alterations in BRCA2.

The team is developing new PDX models of TNBC to better determine which models are sensitive to PARP inhibitors and to get a more comprehensive picture of the determinants of PARP inhibitor sensitivity. They are also conducting an investigator-initiated clinical trial to test whether talazoparib is efficacious in other tumor types with DNA damage repair alterations beyond germline BRCA mutations.

The U.S. Food and Drug Administration has approved three PARP inhibitors so far, olaparib (Lynparza) and rucaparib (Rubraca) to treat certain women who have ovarian cancer with BRCA gene mutations, and niraparib (Zejula) to treat both BRCA mutation-positive and BRCA mutation-negative ovarian cancers.

"Our studies show that PARP inhibitors may have efficacy in selected patients outside of germline BRCA mutation, potentially those with other alterations in DNA damage repair genes," Meric-Bernstam said.

A limitation of the study is that the researchers used a limited number of PDX models and the findings need to be validated in a larger panel of PDXs, Meric-Bernstam said.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Mastitis Breasts - Structures and Types Breast Lumps Breast Lumps-Screening Breast Enhancement Oil 

Recommended Reading
Triple-Negative Breast Cancers - Research Insights
Triple-negative and basal-like breast cancers are breast cancer subgroups that constitute 15% of ......
Diverse Genetic Alterations in Triple-negative Breast Cancers Patients
Despite being treated with chemotherapy to shrink the tumor prior to surgery, most triple-negative ....
Triple-Negative Breast Cancers Exhibit High Biological Diversity
A joint study conducted by Spanish and American has found that triple negative cancers and ......
Diverse Genetic Alterations Detected in Triple-negative Breast Cancers Patients
After patients with triple-negative breast cancer were treated with chemotherapy prior to surgery, ....
Breast Enhancement Oil
Breasts contain mammary glands which produce and secrete milk for feeding and nourishing babies. Tho...
Breast Lumps
Most breast lumps are caused by hormonal changes in a woman and may not be cancerous. Common causes ...
Breast Lumps-Screening
Breast lumps must never be neglected but instead be subjected to medical examination to rule out ......
Breasts - Structures and Types
Different stages of breast development in women and an in-depth look at the breast/bust and its ......
Mastitis
Mastitis is a common cause of tenderness, swelling and pain in breast, owing to inflammation in the ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use